---
layout: post
title: "【图解季报】益佰制药：2022年一季度归母净利润同比下降28.8%，降幅超营收"
date: 2022-04-22 20:16:34 +0800
categories: dongfangcaifuChoiceshuju
tags: 东方财富Choice数据新闻
---
<p>益佰制药于2022年4月23日披露一季报，公司2022年一季度实现营业总收入6.9亿，同比下降16.6%；实现归母净利润5054.9万，同比下降28.8%；每股收益为0.06元。</p><img id="image7" class="autoimg" src="https://dfscdn.dfcfw.com/download/D2C909CF4D52A14B67A108EC80653DC2AD_w800h400.jpg" alt=""><p style="color:#61768C;font-size:0.9em;"></p><img id="image9" class="autoimg" src="https://dfscdn.dfcfw.com/download/D205B088C167A5993EA093E932444390AA_w800h400.jpg" alt=""><p><strong>期间费用率下降6%，经营性现金流大幅下降</strong></p><p>公司2022一季度营业成本1.9亿，同比上升6.2%，营业收入同比下降16.6%，毛利率下降5.8%。期间费用率为62.1%，较去年下降6%。经营性现金流大幅下降87.3%至5261.7万。</p><img id="image12" class="autoimg" src="https://dfscdn.dfcfw.com/download/D26AF6DF722419B59145CB2834A8FAFCBD_w800h400.jpg" alt=""><p style="font-weight:bold;"></p><p style="margin: 10px 0; color: #999">免责声明：本文基于大数据生产，仅供参考，不构成任何投资建议，据此操作风险自担。</p><style>.autoimg {display: block;border: 0;max-width: 100%;margin: 0 auto;} .tbl {border-collapse: collapse;border-spacing: 0;text-align: center;width: 100% !important;} .tbl tr th, .tbl tr td {border: 1px solid #d8e6ff;padding: 5px;text-align: center;} .tbl tr th {color: #fff;background-color: #1c65b0;vertical-align: middle;} .tbl tr td {color: #000;background-color: #fff;} .imgtitle {text-indent: 0;text-align: center;color: #2395F1;} .autosrc {color: #999;display: block;text-align: center;margin-bottom: 5px;}</style>

<http://finews.zning.xyz/html_News/NewsShare.html?infoCode=NW202204222354395246>

[返回东方财富Choice数据新闻](//finews.withounder.com/category/dongfangcaifuChoiceshuju.html)｜[返回首页](//finews.withounder.com/)